immunotherapy

Northwest Biotherapeutics (NWBO) announced the passing of Senior Vice President and General Counsel, Les Goldman. Goldman was a key contributor to NWBO, a biotech firm focused on personalized immune therapies for solid tumor cancers, particularly via its DCVax® platform. NWBO is advancing DCVax®-L for glioblastoma, with UK regulatory review underway. They are also developing DCVax®-Direct for inoperable solid tumors. His responsibilities are being assumed by existing management.

The TROPION-Lung02 and TROPION-Lung04 trials support DATROWAY (datopotamab deruxtecan) combined with immunotherapy as a first-line treatment for advanced NSCLC. TROPION-Lung02 showed a 54.8% objective response rate with DATROWAY and pembrolizumab. Exploratory analyses show promising biomarker associations and the TROPION-Lung04 study found a 57.5% objective response rate when using DATROWAY with rilvegostomig. NeoCOAST-2 data also revealed positive results in the neoadjuvant setting.

Innovent Biologics announced positive Phase 1/2 data for IBI363, a PD-1/IL-2α-bias bispecific antibody, at ASCO 2025. The study showed promising results in immunotherapy-resistant acral and mucosal melanoma (“cold tumors”), demonstrating a 23.3% confirmed objective response rate and 14.8 months median overall survival. A Phase 2 registration trial for IBI363 is underway, offering a potential breakthrough for advanced melanoma treatment.